| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 27.22▲ | 27.22▲ | 27.22▲ | 27.46▲ | 26.58▲ |
| MA10 | 26.83▲ | 26.72▲ | 26.72▲ | 27.01▲ | 27.13▲ |
| MA20 | 26.60▲ | 26.53▲ | 26.53▲ | 26.48▲ | 28.60▼ |
| MA50 | 27.06▲ | 27.10▲ | 27.11▲ | 27.29▲ | N/A |
| MA100 | 28.53▼ | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.192▲ | 0.207▲ | 0.209▲ | 0.220▲ | N/A |
| RSI | 57.596▲ | 57.351▲ | 57.270▲ | 56.072▲ | 38.666▼ |
| STOCH | 87.135▲ | 89.929▲ | 89.929▲ | 99.345▲ | 38.197 |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -0.246▲ | -51.431 |
| CCI | 117.241▲ | 124.815▲ | 124.815▲ | 101.107▲ | -29.003 |
| ▲ BREAK | $FSGS Price Breaks 10 Days High | Set Alert |
|
Friday, May 02, 2025 12:16 AM
Despite a significant increase in net sales, Travere Therapeutics Inc (TVTX) faces hurdles with a reported net loss and anticipated market competition.
|
|
Thursday, May 01, 2025 08:08 PM
The company completed its submission for FDA review of a supplemental New Drug Application (sNDA) for FILSPARI in FSGS, potentially positioning it as the first approved therapy for this condition. If ...
|
|
Thursday, May 01, 2025 01:01 PM
Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/25 | 27.4711 | 27.605 | 27.4711 | 27.60 | 730 |
| 30/04/25 | 26.92 | 27.49 | 26.92 | 27.49 | 2,400 |
| 29/04/25 | 27.56 | 27.56 | 27.49 | 27.56 | 1,158 |
| 28/04/25 | 27.21 | 27.36 | 27.21 | 27.36 | 400 |
| 25/04/25 | 27.23 | 27.31 | 27.15 | 27.31 | 2,738 |
| 24/04/25 | 27.03 | 27.31 | 27.03 | 27.31 | 600 |
| 23/04/25 | 26.98 | 26.98 | 26.8358 | 26.8358 | 985 |
| 22/04/25 | 25.96 | 26.43 | 25.96 | 26.43 | 11,100 |
| 21/04/25 | 25.655 | 25.75 | 25.655 | 25.75 | 200 |
| 17/04/25 | 26.38 | 26.43 | 26.32 | 26.43 | 1,005 |
|
|
||||
|
|
||||
|
|